COVID-19: Vaccines and Therapeutics
One of the biggest challenges communities faced during the COVID-19 pandemic wasn't just the implementation of the COVI
The Food and Drug Administration’s vaccine advisory committee June 15 voted unanimously to recommend updating the current COVID-19 vaccine composition for fall to a monovalent vaccine based on an XBB variant of the virus.
Healthy lifestyles and summertime fun are the themes of AHA’s new social media toolkit promoting COVID-19 vaccination and boosters.
The first data on the safety of a third mRNA COVID-19 vaccine dose among young children show that a third dose is safe for children ages 6 months to 5 years old, similar to findings for doses one and two.
The Centers for Medicare & Medicaid Services (CMS) May 31 released a final rule to better align certain regulatory requirements with the end of the public health emergency (PHE), including rescission of the health care worker vaccine mandate.
By understanding the attitudes and beliefs that drive patient behavior, health care providers and administrators can better design messaging that promotes positive health outcomes, including messages deployed during a public health emergency.
Summertime is right around the corner and AHA’s new social media toolkit promotes COVID-19 vaccination and boosters as a means for keeping kids active and healthy when school’s out.
The Food and Drug Administration April 28 authorized a fourth Pfizer COVID-19 bivalent vaccine dose at least one month after the third dose for certain immunocompromised children aged six months through 4.
In a study of adults hospitalized between February 2022 and February 2023, when the omicron variant predominated, monovalent mRNA vaccination was 76% effective at preventing COVID-19-associated invasive mechanical ventilation and death up to 6 months after the last dose and 56% effective at least…
The Centers for Disease Control and Prevention April 19 recommended a second Moderna or Pfizer COVID-19 bivalent vaccine dose for adults aged 65 and older at least four months after their initial bivalent dose, and for immunocompromised individuals at least two months after their initial bivalent…